Endogenous mitochondrial genes encode critical oxidative phosphorylation components and their mutation results in a set of disorders known collectively as mitochondrial encephalomyopathies. There is intensive interest in modulating mitochondrial function as organelle dysfunction has been associated with numerous disease states. Proteins encoded by the mitochondrial genome cannot be genetically manipulated by current techniques. Here we report the development of a mitochondrial-targeted RNA expression system (mtTRES) utilizing distinct noncoding leader sequences (NCLs) and enabling in vivo expression of small mitochondrial-targeted RNAs. mtTRES expressing small chimeric antisense RNAs was used as translational inhibitors (TLIs) to target endogenous mitochondrial protein expression in vivo. By utilizing chimeric antisense RNA we successfully modulate expression of two mitochondrially-encoded proteins, ATP6 and COXII, and demonstrate the utility of this system in vivo and in human cells. This technique has important and obvious research and clinical implications.
Introduction
Mutations in the mitochondrial genome cause a set of devastating disease conditions categorized as primary respiratory chain diseases, also known as mitochondrial encephalomyopathies (MEs) (DiMauro and Schon, 2003) . Mitochondrial gene therapy has been proposed as a treatment for ME, however, this approach remains controversial as there are limited preclinical data demonstrating efficacy and evidence suggesting that this approach may have significant limitations (Bokori-Brown and Holt, 2006; Manfredi et al., 2002; Perales-Clemente et al., 2011) .
Endogenously encoded mitochondrial proteins function within large well-characterized respiratory complexes that perform oxidative phosphorylation (OXPHOS). The mitochondrial genome is known to harbor hundreds of pathogenic mutations, including ones affecting all of the tRNA genes and over 260 distinct coding mutations. The vast majority of protein-coding gene mutations associated with human mitochondrial disease are missense mutations, accounting for~225 of the pathogenic mitochondrial mutations (www.mitomap.org), implying that mutant protein is usually capable of being expressed in the disease state. We previously discovered and characterized a Drosophila model of ME with an endogenous missense mutation in the ATP6 gene affecting the , 1997; Stock et al., 1999) . ATP6 1 mutant flies contain a missense mutation with high mutant heteroplasmy and exhibit phenotypes analogous to human symptoms including locomotor and progressive neural dysfunction, seizures, myodegeneration, and reduced longevity (Palladino, 2010) .
Competition with mutant protein for incorporation into mature respiratory complexes is likely a major obstacle to a viable mitochondrial gene therapy: a fact that has largely been ignored. This competition may explain the controversial allotopic expression results and remains a formidable obstacle to the treatment of MEs resulting from any endogenous mitochondrial missense mutation. A method to specifically reduce expression of mitochondrial-encoded genes is not known.
Several RNAs are naturally imported into the mitochondria from the cytoplasm and detailed studies have provided critical insight into the import process and import substrates (Lithgow and Schneider, 2010; Schneider and Marechal-Drouard, 2000; Tarassov et al., 2007) . Although the exact mechanism of RNA import into mitochondria is unknown, several pathways have been suggested to mediate mitochondrial RNA import (Mahapatra and Adhya, 1996; Schneider, 2011; Wang et al., 2010) . We have identified a nuclear encoded mitochondrial 5S rRNA isoform and engineered a novel vector to express small RNAs in vivo. We developed a mitochondrial-targeted translational inhibition (TLI) approach using small chimeric RNAs to regulate endogenous mitochondrial protein expression. Here we demonstrate the efficacy of mitochondrialNeurobiology of Disease 69 (2014) [15] [16] [17] [18] [19] [20] [21] [22] 
